Ryght AI and Biorasi Partner to Enhance Clinical Trial Feasibility

Ryght AI has partnered with Biorasi to deliver AI-powered feasibility solutions to biotech and biopharma sponsors, announced in a press release. This strategic collaboration aims to enhance Biorasi's service offerings by integrating Ryght AI's advanced platform for site selection and feasibility.

The partnership leverages Ryght AI's dynamic AI digital twins, which provide continuously updated profiles of global clinical sites. This technology enables more accurate site selection, faster study startup, and improved trial performance by transforming traditional feasibility models into data-driven processes.

Biorasi's clients can expect significant improvements in study startup and execution, including enhanced accuracy in enrollment forecasting, reduced delays through intelligent automation, and optimized costs by minimizing mid-trial delays. This collaboration represents Ryght AI's ongoing expansion of its AI-powered clinical research platform, which maintains SOC Type 2 compliance and fosters real-time communication between sponsors, CROs, and research sites.